Candel Therapeutics Stock

candeltx.comHealthcare / BioTech & PharmaFunding to Date: $67.6MM

Developer of cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.

Register for Details

For more details on financing and valuation for Candel Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Candel Therapeutics.

Register Today

Team

Management Team

Stephen Rocamboli JD
Chief Business Officer
Laura Aguilar Ph.D
Chief Medical Officer
Estuardo Aguilar-Cordova Ph.D
Chief Executive Officer, Chairman and Co-Founder
Daniel Giroux
Vice President, Manufacturing
Brian Guzik Ph.D
Senior Director, Business Development

Board Members

Christopher Martell
Fred Mermelstein Ph.D
Michael Rubin MD
Northpond Ventures
Udi Meirav Ph.D
Edward Benz Jr.
Estuardo Aguilar-Cordova Ph.D
Glenn Mattes
Paul Manning
Alan Smith
Gregory Gailius
Mitchell Finer Ph.D
Sean Stalfort

Other companies like Candel Therapeutics in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Candel Therapeutics Completes $22.5M Series C Funding | FinSMEs
Advantagene, d.b.a. Candel Therapeutics, a company developing proprietary immuno-oncology platforms, closed a $22.5m Series C financing
Updated on: Sep 27, 2023